Cargando…
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an antimitotic drug might further improve this approa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003311/ https://www.ncbi.nlm.nih.gov/pubmed/36902447 http://dx.doi.org/10.3390/ijms24055016 |
_version_ | 1784904576238878720 |
---|---|
author | Krex, Dietmar Bartmann, Paula Lachmann, Doris Hagstotz, Alexander Jugel, Willi Schneiderman, Rosa S. Gotlib, Karnit Porat, Yaara Robel, Katja Temme, Achim Giladi, Moshe Michen, Susanne |
author_facet | Krex, Dietmar Bartmann, Paula Lachmann, Doris Hagstotz, Alexander Jugel, Willi Schneiderman, Rosa S. Gotlib, Karnit Porat, Yaara Robel, Katja Temme, Achim Giladi, Moshe Michen, Susanne |
author_sort | Krex, Dietmar |
collection | PubMed |
description | Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an antimitotic drug might further improve this approach. Here, we tested the combination of TTFields with AZD1152, an Aurora B kinase inhibitor, in primary cultures of newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM). AZD1152 concentration was titrated for each cell line and 5–30 nM were used alone or in addition to TTFields (1.6 V/cm RMS; 200 kHz) applied for 72 h using the inovitro™ system. Cell morphological changes were visualized by conventional and confocal laser microscopy. The cytotoxic effects were determined by cell viability assays. Primary cultures of ndGBM and rGBM varied in p53 mutational status; ploidy; EGFR expression and MGMT-promoter methylation status. Nevertheless; in all primary cultures; a significant cytotoxic effect was found following TTFields treatment alone and in all but one, a significant effect after treatment with AZD1152 alone was also observed. Moreover, in all primary cultures the combined treatment had the most pronounced cytotoxic effect in parallel with morphological changes. The combined treatment of TTFields and AZD1152 led to a significant reduction in the number of ndGBM and rGBM cells compared to each treatment alone. Further evaluation of this approach, which has to be considered as a proof of concept, is warranted, before entering into early clinical trials. |
format | Online Article Text |
id | pubmed-10003311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100033112023-03-11 Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas Krex, Dietmar Bartmann, Paula Lachmann, Doris Hagstotz, Alexander Jugel, Willi Schneiderman, Rosa S. Gotlib, Karnit Porat, Yaara Robel, Katja Temme, Achim Giladi, Moshe Michen, Susanne Int J Mol Sci Article Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an antimitotic drug might further improve this approach. Here, we tested the combination of TTFields with AZD1152, an Aurora B kinase inhibitor, in primary cultures of newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM). AZD1152 concentration was titrated for each cell line and 5–30 nM were used alone or in addition to TTFields (1.6 V/cm RMS; 200 kHz) applied for 72 h using the inovitro™ system. Cell morphological changes were visualized by conventional and confocal laser microscopy. The cytotoxic effects were determined by cell viability assays. Primary cultures of ndGBM and rGBM varied in p53 mutational status; ploidy; EGFR expression and MGMT-promoter methylation status. Nevertheless; in all primary cultures; a significant cytotoxic effect was found following TTFields treatment alone and in all but one, a significant effect after treatment with AZD1152 alone was also observed. Moreover, in all primary cultures the combined treatment had the most pronounced cytotoxic effect in parallel with morphological changes. The combined treatment of TTFields and AZD1152 led to a significant reduction in the number of ndGBM and rGBM cells compared to each treatment alone. Further evaluation of this approach, which has to be considered as a proof of concept, is warranted, before entering into early clinical trials. MDPI 2023-03-06 /pmc/articles/PMC10003311/ /pubmed/36902447 http://dx.doi.org/10.3390/ijms24055016 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krex, Dietmar Bartmann, Paula Lachmann, Doris Hagstotz, Alexander Jugel, Willi Schneiderman, Rosa S. Gotlib, Karnit Porat, Yaara Robel, Katja Temme, Achim Giladi, Moshe Michen, Susanne Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title | Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title_full | Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title_fullStr | Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title_full_unstemmed | Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title_short | Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas |
title_sort | aurora b kinase inhibition by azd1152 concomitant with tumor treating fields is effective in the treatment of cultures from primary and recurrent glioblastomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003311/ https://www.ncbi.nlm.nih.gov/pubmed/36902447 http://dx.doi.org/10.3390/ijms24055016 |
work_keys_str_mv | AT krexdietmar aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT bartmannpaula aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT lachmanndoris aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT hagstotzalexander aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT jugelwilli aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT schneidermanrosas aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT gotlibkarnit aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT poratyaara aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT robelkatja aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT temmeachim aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT giladimoshe aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas AT michensusanne aurorabkinaseinhibitionbyazd1152concomitantwithtumortreatingfieldsiseffectiveinthetreatmentofculturesfromprimaryandrecurrentglioblastomas |